Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
205 hedge funds and large institutions have $2.38B invested in Mirati Therapeutics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 82 increasing their positions, 66 reducing their positions, and 41 closing their positions.
196% more call options, than puts
Call options by funds: $33.6M | Put options by funds: $11.3M
24% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 66
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
0% less capital invested
Capital invested by funds: $2.38B → $2.38B (-$18.1K)
7% less funds holding
Funds holding: 220 → 205 (-15)
37% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 41
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$34.2M |
| 2 |
Morgan Stanley
New York
|
+$32.7M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$28.5M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$22.8M |
| 5 |
AG
Artal Group
Luxembourg
|
+$21.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$35.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$24M |
| 3 |
CC
Casdin Capital
New York
|
-$20M |
| 4 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$18.6M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$11.9M |
MRTX Hedge Fund Activity: Q2 2023 in Review
205 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q2 2023, worth a combined $2.38B — down 0% from $2.38B a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of MRTX and 26 opened new positions — a net loss of 15 holders — while 66 trimmed existing stakes and 82 added.
The largest buyer was RTW Investments, adding an estimated $34.2M. The largest seller was Perceptive Advisors, cutting an estimated $35.2M.
- 205 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q2 2023, down from 220 in Q1 2023.
- Funds reported $2.38B of Mirati Therapeutics, Inc. Common Stock stock for Q2 2023, down 0% quarter-over-quarter.
- 26 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q2 2023 and 41 closed out, a net change of -15 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q2 2023 was RTW Investments, an estimated $34.2M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q2 2023 was Perceptive Advisors, an estimated $35.2M sold.
Based on aggregated 13F filings for Q2 2023.